PCRX (Pacira BioSciences, Inc.) Stock Financials & Earnings

PCRXPacira BioSciences, Inc.

Mkt Cap$971M

Revenue (TTM)$726M

Net Income (TTM)$7M

EPS (TTM)$0.15

Free Cash Flow (TTM)$137M

Gross Margin71.5%

Op. Margin3.9%

Net Margin1.0%

FCF Margin18.8%

P/S Ratio (TTM)1.3x

P/E Ratio (TTM)138.1x

YoY Rev Growth+3.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$160M	$111M	-$3M
Q2 23	$169M	$121M	$40M
Q3 23	$164M	$124M	$18M
Q4 23	$181M	$134M	$33M
Q1 24	$167M	$120M	$13M
Q2 24	$178M	$134M	$28M
Q3 24	$169M	$130M	-$140M
Q4 24	$187M	$147M	$25M
Q1 25	$169M	$135M	$2M
Q2 25	$181M	$140M	$8M
Q3 25	$180M	$145M	$6M
Q4 25	$197M	$99M	$11M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$17M	$29M	$42M	—
Q2 23	$19M	$27M	$37M	—
Q3 23	$21M	$30M	$38M	—
Q4 23	$19M	$30M	$36M	—
Q1 24	$18M	$33M	$39M	—
Q2 24	$20M	$29M	$39M	—
Q3 24	$19M	$31M	$43M	—
Q4 24	$24M	$29M	$50M	—
Q1 25	$25M	$31M	$56M	—
Q2 25	$28M	$38M	$51M	—
Q3 25	$26M	$33M	$58M	—
Q4 25	$37M	—	—	$102M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$36M	$138M	$174M
Q2 23	$87M	$134M	$221M
Q3 23	$99M	$136M	$235M
Q4 23	$153M	$125M	$279M
Q1 24	$184M	$142M	$326M
Q2 24	$247M	$157M	$404M
Q3 24	$246M	$208M	$454M
Q4 24	$277M	$208M	$485M
Q1 25	$284M	$210M	$494M
Q2 25	$300M	$145M	$446M
Q3 25	$148M	$99M	$246M
Q4 25	$159M	$80M	$238M

Shares Outstanding

Revenue Per Employee

Revenue / Employee